Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity

OBJECTIVE: Letrozole is a non-steroidal aromatase inhibitor (AI) used to treat hormone receptor positive (HR+) breast cancer. Variability in letrozole efficacy and toxicity may be partially attributable to variable systemic drug exposure, which may be influenced by germline variants in the enzymes r...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Pharmacogenet Genomics
Asıl Yazarlar: Hertz, Daniel L., Douglas, Julie A., Kidwell, Kelley M., Gersch, Christina L., Desta, Zeruesenay, Storniolo, Ana-Maria, Stearns, Vered, Skaar, Todd C, Hayes, Daniel F, Henry, N. Lynn, Rae, James M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8185249/
https://ncbi.nlm.nih.gov/pubmed/34096894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000429
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller